WuXi AppTec Group is a leading pharmaceutical, biopharmaceutical, and medical device capability and technology platform company with 16,000 employees globally, including more than 13,000 dedicated scientists. Through its 28 R&D sites worldwide, and a total of 6.0 million square feet of office, laboratory and manufacturing space, WuXi Group provides comprehensive platform capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics. Today, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients.
Our vision is to become the most comprehensive capability and technology platform to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” WuXi has received many distinguished recognitions, including the “2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award”(2017), “Company of the Year Award”(2016), “Asian CRO Company of the Year” Award (2015), the “North American Open-Access R&D Technology Leadership” Award (2015), “Best Company in an Emerging Market” (2014). In 2016, 16 from the 22 US FDA approved drugs are from WuXi's collaborators; in 2015, 33 from the 45 US FDA approved drugs are from WuXi's collaborators.
Drug Discovery, Bioanalytical, Lab Testing, Clinical and Regulatory, API Development and Manufacturing, Genomics, Drug Development, Biological Reagents, Biologics, Medical Device, Chemistry, Toxicology, Cell and Gene Therapy, Contract Research Organization
Shanghai, Shanghai, China